RE:RE:RE:Napkin Math - SCRN P/E Value Regarding Add Biomedical's test device approvals, I would like to add that Lena mentioned in a tweet on February 23 that Add Biomedical's products were already in use in hospitals in South Korea. So I guess it will have a positive impact on the approvals here in North America and the marketing of Add Bio's products.
Where could we find out more details on Add Biomedical? Are the products on the market?
Yes, they are being used in hospitals currently in Asia:
Smokey1958 wrote:
After all the napkin math from Graylo this is the most informed response you could come up with???
The simplicity of your retort is based solely on the current sp. Surely you could move beyond the realm of elementary school arithmetic and acknowledge the importance of considering fundamentals and facts including but not exclusive to the following:
* obvious manipulation of the stock
* the release of Q4 2021 and 2021 Annual financials
* ongoing covid testing which by company NRs appears to be increasing again
* significant revenues and profits during the first 3 quarters as a public company
* significant purchases of common shares by insiders
....as well as some speculative developments that may or may not signal more positive news, like
* the removal of anything covid from the updated DM website.
* the first of what investors would hope is a stream of approvals to sell Add Biomedical test devices
* the growth of Concierge Medical
While Graylo's numbers for upcoming quarters including an NR on Q1 2022 are purely speculative, based on the current no. of outstanding shares, analyses and fundamentals the napkin math is pretty solid imho. Unfortunately, as is the case with the stock of hundreds of companies, it is a challenge to watch ScreenPro stock to be so formidably manipulated.
MugglesOhana wrote: We will need another reverse split of 10:1 to achieve such prices